A population‐based analyses of the evolving management of cN1M0 prostate cancer in the PSMA‐PET era

Documenti analoghi

• Does total lesion prostate‐specific membrane antigen (PSMA) activity on 68Ga‐PSMA PET/CT correlate with PSA and prostatectomy histopathological/clinical outcomes in patients with localised primary prostate cancer?
  di: Jeremy Cheng, et al.
  Pubblicazione: (2025)
• Oncological outcomes post focal low‐dose‐rate brachytherapy in low‐intermediate risk prostate cancer
  di: Mohammadmehdi Adhami, et al.
  Pubblicazione: (2026)
• Bleeding us dry: The financial impact of full blood examinations in the immediate postoperative period
  di: Bodie Chislett, et al.
  Pubblicazione: (2024)
• PSMA PET/CT findings in high‐risk biochemical recurrence after local treatment of prostate cancer
  di: Nicole Handa, et al.
  Pubblicazione: (2025)
• Cost‐effectiveness analysis of a biopsy‐free diagnostic strategy for prostate cancer using mpMRI and PSMA‐PET/CT
  di: Joshua Yi Min Tung, et al.
  Pubblicazione: (2026)